Evaluating Twist Bioscience: Insights From 5 Financial Analysts

Throughout the last three months, 5 analysts have evaluated Twist Bioscience TWST, offering a diverse set of opinions from bullish to bearish.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $55.8, with a high estimate of $65.00 and a low estimate of $46.00. Observing a 20.65% increase, the current average has risen from the previous average price target of $46.25.

Analyzing Analyst Ratings: A Detailed Breakdown

The analysis of recent analyst actions sheds light on the perception of Twist Bioscience by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Twist Bioscience. This insight gives a snapshot of analysts' perspectives on the current state of the company.
• Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Twist Bioscience compared to the broader market.
• Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Twist Bioscience's stock. This examination reveals shifts in analysts' expectations over time.

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Twist Bioscience's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on Twist Bioscience analyst ratings.

All You Need to Know About Twist Bioscience

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of its revenue from the United States.

A Deep Dive into Twist Bioscience's Financials

Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.

Revenue Growth: Twist Bioscience's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 25.13%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: Twist Bioscience's net margin excels beyond industry benchmarks, reaching -60.41%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): Twist Bioscience's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -7.91%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): Twist Bioscience's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -6.34% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: Twist Bioscience's debt-to-equity ratio is below the industry average at 0.16, reflecting a lower dependency on debt financing and a more conservative financial approach.

Analyst Ratings: What Are They?

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.